Tight Junctions and the Tumor Microenvironment

Current Pathobiology Reports

Volumn 4, Issue 3, 2016, Pages 135-145

  Salvador, Ellaine ^a   Burek, Malgorzata ^a   Förster, Carola Y ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cancer; Intercellular permeability; Metastasis; Tight junctions; Tumor microenvironment

Indexed keywords

EID: 85003026481     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-016-0106-6     Document Type: Review

References (101)

1. • Leech AO, Cruz RG, Hill AD, Hopkins AM (2015) Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Ann Transl Med 3(13):184. This review highlights cases wherein the gain of tight junction proteins has been associated with signals promoting tumor progression. Epub 2015/09/15
2. Tervonen TA, Partanen JI, Saarikoski ST, Myllynen M, Marques E, Paasonen K et al (2011) Faulty Epithelial Polarity Genes and Cancer. Adv Cancer Res 111:97–161
3. Cavallaro U, Christofori G (2004) Multitasking in tumor progression - Signaling functions of cell adhesion molecules. Ann Ny Acad Sci. 1014:58–66
4. Bogenrieder THM (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524–6536
5. Tsukita S, Yamazaki Y, Katsuno T, Tamura A, Tsukita S (2008) Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 27(55):6930–6938
6. Matter K, Balda MS (2007) Epithelial tight junctions, gene expression and nucleo-junctional interplay. J Cell Sci 120(9):1505–1511
7. • Brücher B, Jamall, I. S (2014) Cell–cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment. Cell Physiol Biochem 34(2):213–243. In this review article, cell to cell communication within the tumor microenvironment is discussed. It also provides a description of carcinogenesis and underlying mechanisms involved therein
8. Tamura A, Kitano Y, Hata M, Katsuno T, Moriwaki K, Sasaki H et al (2008) Megaintestine in claudin-15-deficient mice. Gastroenterology 134(2):523–534
9. Forster C (2008) Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 130(1):55–70
10. Eccles SA, Welch DR (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369(9574):1742–1757
11. Martin TA, Mansel RE, Jiang WG (2002) Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells. J Cell Physiol 192(3):268–275
12. Hollande F, Blanc EM, Bali JP, Whitehead RH, Pelegrin A, Baldwin GS et al (2001) HGF regulates tight junctions in new nontumorigenic gastric epithelial cell line. Am J Physiol-Gastr L 280(5):G910–G921
13. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S et al (1993) Occludin - a novel integral membrane-protein localizing at tight junctions. J Cell Biol 123(6):1777–1788
14. Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H et al (2000) Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 11(12):4131–4142
15. Raleigh DR, Marchiando AM, Zhang Y, Shen L, Sasaki H, Wang YM et al (2010) Tight junction-associated MARVEL proteins MarvelD3, tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell 21(7):1200–1213
16. • Cravo AS, Carter E, Erkan M, Harvey E, Furutani-Seiki M, Mrsny R (2015) Hippo pathway elements Co-localize with Occludin: A possible sensor system in pancreatic epithelial cells. Tissue barriers 3(3):e1037948. In this paper, it was shown that the cellular localization of occludin is similar in normal and cancerous human pancreatic biopsies. Epub 2015/10/10
17. Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, Sawada N (2006) Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res 66(18):9125–9133
18. Wang ZL, Mandell KJ, Parkos CA, Mrsny RJ, Nusrat A (2005) The second loop of occludin is required for suppression of Raf1-induced tumor growth. Oncogene 24(27):4412–4420
19. Orban E, Szabo E, Lotz G, Kupcsulik P, Paska C, Schaff Z et al (2008) Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol Oncol Res 14(3):299–306
20. Kurrey NK, Amit K, Bapat SA (2005) Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 97(1):155–165
21. Tobioka H, Isomura H, Kokai Y, Tokunaga Y, Yamaguchi J, Sawada N (2004) Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol 35(2):159–164
22. Martin TA, Mansel RE, Jiang WG (2010) Loss of occludin leads to the progression of human breast cancer. Int J Mol Med 26(5):721–732
23. Lemieux E, Bergeron S, Durand V, Asselin C, Saucier C, Rivard N (2009) Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int J Cancer 125(7):1575–1586
24. Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65(21):9603–9606
25. • Capaldo CT, Nusrat, A (2015) Claudin switching: physiological plasticity of the tight junction. Semin Cell Dev Biol 42:22–9. This review focuses on changes in claudin expression within the epithelial cells of the gastrointestinal tract, where claudin differentiation results in several physiologically distinct TJs within the lifetime of the cell
26. Kim TH, Huh JH, Lee S, Kang H, Kim GI, An HJ (2008) Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology 53(1):48–55
27. Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S et al (2007) Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20(2):139–143
28. Tokes AM, Kulka J, Paku S, Szik A, Paska C, Novak PK et al (2005) Claudin-1,-3 and-4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7(2):R296–R305
29. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E et al (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22(13):2021–2033
30. Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N et al (2006) Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 37(5):569–577
31. Bazzoni G (2003) The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 15:525–530
32. Ebnet K, Suzuki A, Ohno S, Vestweber D (2004) Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci 117(Pt 1):19–29
33. • Tian Y, Tian YM, Zhang WJ, Wei F, Yang J, Luo XJ, et al. (2015) Junctional adhesion molecule-A, an epithelial-mesenchymal transition inducer, correlates with metastasis and poor prognosis in human nasopharyngeal cancer. Carcinogenesis 36(1):41–8. Data gathered from this study indicate novel functions in the JAM-A repertoire and clinical implications for the treatment of patients with nasopharyngeal carcinoma
34. McNeil E, Capaldo CT, Macara IG (2006) Zonula occludens-1 function in the assembly of tight junctions in Madin-Darby canine kidney epithelial cells. Mol Biol Cell 17(4):1922–1932
35. Fanning AS, Anderson JM (2009) Zonula occludens-1 and-2 are cytosolic scaffolds that regulate the assembly of cellular junctions. Ann N. Y. Acad Sci 1165:113–120
36. Pozzi A, Zent R (2010) ZO-1 and ZONAB Interact to Regulate Proximal Tubular Cell Differentiation. J Am Soc Nephrol 21(3):388–390
37. Kaihara T, Kusaka T, Nishi M, Kawamata H, Imura J, Kitajima K et al (2003) Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are closely related to liver metastasis. J Exp Clin Canc Res. 22(1):117–123
38. Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, Foidart JM et al (2007) beta-Catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 185(1–3):61–65
39. • Balkwill FR, Capasso, M., Hagemann, T (2012) The Tumor Microenvironment at a Glance. J Cell Sci 125:5591–6. This review describes the functions of major non-malignant cell types that are found in the tumor microenvironment of most human and experimental cancers
40. Mroue R, Bissell MJ (2013) Three-dimensional cultures of mouse mammary epithelial cells. Methods Mol Biol 945:221–250
41. Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Gene Dev. 27(20):2192–2206
42. • Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423–37. This review discusses the paradoxical roles of the tumor microenvironment during specific stages of cancer progression and metastasis
43. Martin TA, Jiang WG (2009) Loss of tight junction barrier function and its role in cancer metastasis. Bba-Biomembranes. 1788(4):872–891
44. Latorre IJ, Frese, K.K., Javier, R.T. Tight Junction Proteins and Cancer. In: Madame Curie Bioscience Database [Internet] Austin (TX): Landes Bioscience. 2000; http://www.ncbi.nlm.nih.gov/books/NBK6540/
45. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454
46. Ohkubo T, Ozawa M (2004) The transcription factor Snail downregulates the tight junction components independently of E-cadherin downregulation. J Cell Sci 117(Pt 9):1675–1685 Epub 2004/04/13
47. Dubois LG, Campanati L, Righy C, D’Andrea-Meira I, Spohr TCLDE, Porto-Carreiro I, et al. (2014) Gliomas and the vascular fragility of the blood brain barrier. Frontiers in Cellular Neuroscience 8
48. Salvador E, Burek M, Förster CY (2015) Stretch and/or oxygen glucose deprivation (OGD) in an in vitro traumatic brain injury (TBI) model induces calcium alteration and inflammatory cascade. Front Cel Neurosci 9:323
49. Kröll S (2009) E-GJ, Thanabalasundaram G, Panpumthong P, Schrot S, Hartmann C, Galla HJ. Control of the blood-brain barrier by glucocorti- coids and the cells of the neurovascular unit. Ann Ny Acad Sci. 1165:228–239
50. Kaal ECA, Vecht CJ (2004) The management of brain edema in brain tumors. Curr Opin Oncol 16(6):593–600
51. Salvador E, Shityakov S, Forster C (2014) Glucocorticoids and endothelial cell barrier function. Cell Tissue Res 355(3):597–605 Epub 2013/12/20
52. Forster C, Silwedel C, Golenhofen N, Burek M, Kietz S, Mankertz J et al (2005) Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol-London. 565(2):475–486
53. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D (2008) Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 586(Pt 7):1937–1949 Epub 2008/02/09
54. Burek M, Forster CY (2009) Cloning and characterization of the murine claudin-5 promoter. Mol Cell Endocrinol 298(1–2):19–24
55. Romero IA, Radewicz K, Jubin E, Michel CC, Greenwood J, Couraud PO et al (2003) Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett 344(2):112–116
56. Hue CD, Cho FS, Cao SQ, Bass CR, Meaney DF, Morrison B (2015) Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein. J Cerebr Blood F Met 35(7):1191–1198
57. Harke N, Leers J, Kietz S, Drenckhahn D, Forster C (2008) Glucocorticoids regulate the human occludin gene through a single imperfect palindromic glucocorticoid response element. Mol Cell Endocrinol 295(1–2):39–47
58. Keil JM, Liu X, Antonetti DA (2013) Glucocorticoid induction of occludin expression and endothelial barrier requires transcription factor p54 NONO. Invest Ophthalmol Vis Sci 54(6):4007–4015 Epub 2013/05/04
59. Forster C, Kahles T, Kietz S, Drenckhahn D (2007) Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol 580:937–949 Epub 2007/02/24
60. Kleinschnitz C, Blecharz K, Kahles T, Schwarz T, Kraft P, Gobel K et al (2011) Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke 42(4):1081–1089
61. Blecharz KGDD, Förster CY (2008) Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J Cereb Blood Flow Metab 28(6):1139–1149
62. Argaw ATGB, Zhang Y, Zameer A, John GR (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. PNAS 106(6):1977–1982
63. Kim H, Lee JM, Park JS, Jo SA, Kim YO, Kim CW et al (2008) Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun 372(1):243–248 Epub 2008/05/20
64. Karnati HK, Panigrahi M, Shaik NA, Greig NH, Bagadi SA, Kamal MA et al (2014) Down regulated expression of Claudin-1 and Claudin-5 and up regulation of beta-catenin: association with human glioma progression. CNS Neurol Disord: Drug Targets 13(8):1413–1426 Epub 2014/10/28
65. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H et al (2000) Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 100(3):323–331
66. Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K (2012) The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 33(5–6):579–589
67. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y et al (2002) Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156(6):1099–1111
68. Hintsala HR, Siponen M, Haapasaari KM, Karihtala P, Soini Y (2013) Claudins 1, 2, 3, 4, 5 and 7 in solar keratosis and squamocellular carcinoma of the skin. Int J Clin Exp Pathol 6(12):2855–2863
69. Rachow S, Zorn-Kruppa M, Ohnemus U, Kirschner N, Vidal-y-Sy S, von den Driesch P et al (2013) Occludin Is Involved in Adhesion, Apoptosis, Differentiation and Ca2 + -Homeostasis of Human Keratinocytes: Implications for Tumorigenesis. Plos One 8(2):55116
70. Morita K, Tsukita S, Miyachi Y (2004) Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen’s disease. Brit J Dermatol. 151(2):328–334
71. Förster CMS, Wärri A, Kietz S, Becker D, Hultenby K (2002) Warner, M and J Gustafsson. Involvement of estrogen receptor ß in terminal differentiation of mammary gland epithelium PNAS. 99:15578–15583
72. • Yang Y, Cheon S, Jung MK, Song SB, Kim D, Kim HJ, et al. (2015) Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway. Biochemical and biophysical research communications. 459(3):379–86. This study shows that exogenous IL-18 enhanced breast cancer cell migration and suppressed the expression of the tight junction proteins claudin- 1, 3, 4, and 12 in MCF-7 cells. Knockdown of claudin-3, 4, and 12, but not claudin-1, increased breast cancer migration with maximal effects observed in claudin-12 siRNA-transfected cells
73. Sauer T, Pedersen MK, Ebeltoft K, Naess O (2005) Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 16(4):193–198 Epub 2005/07/29
74. Seok SH, Kang SH, Lee SJ, Hwang TY, Bae YK (2007) Reduced expression of claudin-7 correlates with invasiveness and nuclear grade of breast carcinomas. Korean J Pathol. 41(3):158–164
75. • Todd MC, Petty HM, King JM, Marshall BNP, Sheller RA, Cuevas ME (2015) Overexpression and delocalization of claudin-3 protein in MCF-7 and MDA-MB-415 breast cancer cell lines. Oncol Lett 10(1):156–62. This study used two breast cancer cell lines to examine the effects of claudin-3 to cell motility which is an important factor in tumor progression
76. Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Modern Pathol 18(4):511–518
77. Takai E, Tan XD, Tamori Y, Hirota M, Egami H, Ogawa M (2005) Correlation of translocation of tight junction protein Zonula occludens-1 and activation of epidermal growth factor receptor in the regulation of invasion of pancreatic cancer cells. Int J Oncol 27(3):645–651
78. Martin TA, Watkins G, Mansel RE, Jiang WG (2004) Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer 40(18):2717–2725
79. • Martin TA, Mason MD, Jiang WG (2014) HGF and the regulation of tight junctions in human prostate cancer cells. Oncol Rep 32(1):213–24. This study is the first to demonstrate that hepatocyte growth factor (HGF) regulates tight junction function in human prostate cells. It shows how HGF affects the redistribution of various zonula occludens and concurrent loss of claudin- 1 and 5
80. Shin DY, Lee WS, Jung JH, Hong SH, Park C, Kim HJ et al (2013) Flavonoids from Orostachys japonicus A. Berger Inhibit the Invasion of LnCaP Prostate Carcinoma Cells by Inactivating Akt and Modulating Tight Junctions. Int J Mol Sci 14(9):18407–18420
81. Suh YYC, Kim RK, Lim EJ, Oh YS, Hwang SG, An S, Yoon G, Gye MC, Yi JM, Kim MJ (2013) Lee SJ Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32:1743–1868
82. Brokalaki EI, Weber F, Sotiropoulos GC, Daoudaki M, Cicinnati VR, Beckebaum S (2012) Claudin-7 expression in hepatocellular carcinoma. Transpl Proc 44(9):2737–2740 Epub 2012/11/14
83. Sakaguchi T, Suzuki S, Higashi H, Inaba K, Nakamura S, Baba S et al (2008) Expression of tight junction protein claudin-5 in tumor vessels and sinusoidal endothelium in patients with hepatocellular carcinoma. J Surg Res 147(1):123–131
84. Wada M, Tamura A, Takahashi N, Tsukita S (2013) Loss of Claudins 2 and 15 From Mice Causes Defects in Paracellular Na + Flow and Nutrient Transport in Gut and Leads to Death from Malnutrition. Gastroenterology 144(2):369–380
85. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C et al (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Investig 115(7):1765–1776 Epub 2005/06/21
86. • Süren D, Yildirim M, Kaya V, Alikanoglu AS, Bulbuller N, Yildiz M, et al. (2014) Loss of tight junction proteins (Claudin 1, 4, and 7) correlates with aggressive behavior in colorectal carcinoma. Med Sci Monitor 20:1255–62. This study investigated the importance of loss of claudin- 1, 4 and 7 expression and their relation to tumor progression in colorectal cancer patients. It shows that their decreased expression in colorectal cancer seems to have critical effects on cell proliferation, motility, invasion, and immune response against the tumor
87. • Hahn-Strömberg V, Askari S, Befekadu R, Matthiessen P, Karlsson S, Nilsson TK (2014) Polymorphisms in the CLDN1 and CLDN7 genes are related to differentiation and tumor stage in colon carcinoma. Apmis 122(7):636–42. This study looked at the allele frequencies of single nucleotide polymorphisms in claudin- 1 and 7 using pyrosequencing of colon cancer tissue. An association between the polymorphisms and tumor differentiation was found
88. Buhrmann CSP, Kraehe P, Popper B, Goel A, Shakibaei M (2015) Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol 98(1):51–68
89. Rogers MA, Kalter V, Marcias G, Zapatka M, Barbus S, Lichter P (2016) CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation. J Cancer Res Clin Oncol 142(1):225–237 Epub 2015/08/06
90. Ikeo K, Oshima T, Shan J, Matsui H, Tomita T, Fukui H et al (2015) Junctional adhesion molecule-A promotes proliferation and inhibits apoptosis of gastric cancer. Hepato-Gastroenterol. 62(138):540–545
91. Tobioka H, Tokunaga Y, Isomura H, Kokai Y, Yamaguchi J, Sawada N (2004) Expression of occludin, a tight-junction-associated protein, in human lung carcinomas. Virchows Arch 445(5):472–476
92. Sormunen R, Paakko P, Kaarteenaho-Wiik R, Soini Y (2007) Differential expression of adhesion molecules in lung tumours. Histopathology 50(2):282–284 Epub 2007/01/16
93. Soini Y (2012) Tight junctions in lung cancer and lung metastasis: a review. Int J Clin Exp Pathol. 5(2):126–136 Epub 2012/03/09
94. Wang ZL, Mandell KJ, Parkos CA, Mrsny RJ, Nusrat A (2005) The second loop of occludin is required for suppression of Raf1-induced tumor growth. Oncogene 24(27):4412–4420
95. Neuhaus W, Samwer F, Kunzmann S, Muellenbach RM, Wirth M, Speer CP et al (2012) Lung endothelial cells strengthen, but brain endothelial cells weaken barrier properties of a human alveolar epithelium cell culture model. Differentiation 84(4):294–304 Epub 2012/10/02
96. Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7(2):139–147
97. Brücher B, Jamall IS (2014) Cell-Cell Communication in the Tumor Microenvironment, Carcinogenesis, and Anticancer Treatment. Cell Physiol Biochem 34:213–243
98. Landskron G, Dela Fuente M, Thuwajit P, Thuwajit C, Hermoso M (2014) Chronic Inflammation and Cytokines in the Tumor Microenvironment. Journal of Immunology Research. 2014:19. doi:10.1155/2014/149185
99. Quante M, Varga J, Wang TC, Greten FR (2013) The gastrointestinal tumor microenvironment. Gastroenterology 145(1):63–78. doi:10.1053/j.gastro.2013.03.052
100. Capaldo C, Nusrat A (2009) Cytokine regulation of tight junctions. Biochimica et Biophysica Acta (BBA) -. Biomembranes. 1788(4):864–871
101. Capaldo C, Farkas A, Hilgarth R, Krug S, Wolf M, Benedik J et al (2014) Proinflammatory cytokine-induced tight junction remodeling through dynamic self-assembly of claudins. Mol Biol Cell 25(18):2710–2719. doi:10.1091/mbc.E14-02-0773.99